

Contents

<i>Foreword</i>	vi
<i>The subtypes of alpha interferon and their importance</i> N.B. Finter	1
<i>The interferons: a biological system with therapeutic potential in viral infections</i> F. Dianzani, S. Baron	7
<i>Hepatitis C virus: modes of transmission</i> L. Rodrigo Sáez	18
<i>Predictors of response to interferon in chronic hepatitis C</i> A. Alberti et al.	27
<i>The significance of antibodies to interferon</i> G. Antonelli, F. Dianzani	33
<i>Carcinogenesis in viral hepatitis</i> L.I. Castells	40
<i>Clinical use of interferon in haematology</i> M.T. Petrucci, F. Mandelli	48
<i>Review of the clinical use of interferon in oncology (solid tumours)</i> H. Strander	57
<i>The use of interferon in HIV</i> M. Moroni, A. D'Arminio Monforte	70
<i>Alpha interferon treatment of chronic hepatitis C: regimen optimisation to improve the response rate</i> A. Bellobuono et al.	81
<i>Valuation of direct costs of treatment versus non-treatment with interferon in hepatitis C: a cost effectiveness analysis</i> S. Capri	88
<i>Mechanisms of liver fibrogenesis and the effects of interferon</i> A. Mallat et al.	96
<i>Management of chronic hepatitis B</i> G.M. Dusheiko	102
<i>Interferon treatment of acute HCV infection</i> N.C. Tassopoulos	109



<i>Interferon treatment of chronic hepatitis C: a randomized, controlled study of human lymphoblastoid α-interferon versus no therapy</i> M.P. Civeira <i>et al.</i>	113
<i>Hepatitis C – the histological response to interferon treatment</i> R.D. Goldin	123
<i>Treatment of chronic hepatitis B: interferon combination with prednisolone</i> J. M. Sánchez-Tapias	125
<i>Interferon therapy of hepatitis B and hepatitis C in Far Eastern patients</i> Y.F. Liaw	132
<i>Pre-treatment variables and their effect on interferon response rate in chronic hepatitis B</i> K. Krogsgaard and EUROHEP	139
<i>Natural lymphoblastoid α-interferon in the prevention of hepatocellular carcinoma in high-risk hepatitis B surface antigen (HBsAg) positive carriers: a 5-year follow-up</i> C. J. Oon	145
<i>Treatment of patients with hepatitis B virus mutations</i> C. Trépo <i>et al.</i>	152
<i>A meta-analysis of lymphoblastoid α-interferon in the treatment of severe refractory condylomata acuminata</i> K.F. Trofatter <i>et al.</i>	156
<i>Interferon in the treatment of chronic lymphoproliferative disorders: Italian experience</i> S. Tura <i>et al.</i>	167
<i>Predictors of response to alpha interferon in oncology</i> D. Amadori <i>et al.</i>	171
<i>Interferons in the treatment of neuroendocrine tumours</i> K. Öberg	180
<i>Cyclophosphamide, lymphoblastoid alpha interferon, betamethasone (CIB) for treatment of newly diagnosed patients with multiple myeloma stages II and III — a phase IB/II trial from the myeloma group of central Sweden</i> H. Mellstedt <i>et al.</i>	189
<i>Use of lymphoblastoid alpha interferon for the treatment of polycythaemia vera</i> V. Rizzoli <i>et al.</i>	195
<i>Interferon treatment of renal cancer</i> P. Ferrari <i>et al.</i>	202

<i>Treatment with human lymphoblastoid interferon can rescue some chronic myeloid leukaemia patients resistant to recombinant interferon $\alpha 2$ and without anti-interferon-$\alpha 2$ antibodies</i>	207
J.L. Steegmann <i>et al.</i>	
<i>Alpha interferon in the maintenance of chronic phase chronic myeloid leukaemia</i>	215
N.C. Allan	
<i>Aerosolised lymphoblastoid α-interferon treatment in pulmonary tuberculosis: a therapeutic approach</i>	224
A. Bisetti <i>et al.</i>	
<i>Effects of human lymphoblastoid alpha-interferon on Chlamydia trachomatis urethritis</i>	233
G. Zuccati <i>et al.</i>	
<i>Interferon and autoimmunity: implications for managing side-effects</i>	238
C.P. Strassburg, M.P. Manns	
<i>Interferon resistance and future directions in the treatment of viral hepatitis</i>	248
J. Prieto, O. Beloqui	
<i>Gene therapy: general principles and application to the treatment of viral hepatitis</i>	255
J. Ruiz	
<i>Prospects of gene therapy in haematology and oncology</i>	264
R. Foà, A. Cignetti, L. Riera, A. Gillio Tos and A. Guarini	

